Back to search

Article

Novel polymeric fluoropyrimidine CF10 demonstrates superior therapeutic index and survival advantage in patient-derived models of 5-fluorouracil-refractory colorectal cancer

2026-04-08

Abstract excerpt

<h4>Background</h4> Fluoropyrimidines, specifically 5-fluorouracil (5-FU), remain the cornerstone of colorectal cancer (CRC) therapy. However, intrinsic and acquired resistance, alongside dose-limiting systemic toxicities, often result in treatment failure and disease relapse. There is a pressing clinical need for next-generation fluoropyrimidines that can retain the antitumor activity in 5-FU-refractory CRC mode...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8284653b-0cd2-5813-b481-dac5bfc45472
DOI
10.64898/2026.04.05.716582
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel polymeric fluoropyrimidine CF10 demonstrates superior therapeutic index and survival advantage in patient-derived models of 5-fluorouracil-refractory colorectal cancerDOI 10.64898/2026.04.05.716582
Select a neighboring publication to make it the new centre.